What question did this study set out to answer?

This study aims to investigate the safety and feasibility of oral azacitidine combined with chemotherapy in patients with relapsed DLBCL.

June 23, 2026Annals of Hematology0 citationsOpen Access

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

BHBrian Hess NWNina D. Wagner-Johnston LHLindsey Hendrickson

Key Points

This study aims to investigate the safety and feasibility of oral azacitidine combined with chemotherapy in patients with relapsed DLBCL.
Phase I trial assessing two dose levels of oral azacitidine with standard chemotherapy (R-ICE).
Target population includes relapsed DLBCL patients eligible for autologous stem cell transplantation.
Evaluated safety and feasibility outcomes.
Safety profiles of both doses of azacitidine were acceptable without unexpected toxicities.
Combination therapy demonstrated potential to enhance chemotherapy response.

Abstract

Abstract Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.

问 AI

Bookmark

View Full Paper